相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Vildagliptin Attenuates Huntington's Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model
Noha H. Sayed et al.
NEUROTHERAPEUTICS (2020)
Increased Immune Activation by Pathologic α-Synuclein in Parkinson's Disease
Veselin Grozdanov et al.
ANNALS OF NEUROLOGY (2019)
Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease A Secondary Analysis of the Exenatide-PD Trial
Dilan Athauda et al.
JAMA NEUROLOGY (2019)
Do subjects with minimal motor features have prodromal Parkinson disease?
Yaping Chu et al.
ANNALS OF NEUROLOGY (2018)
Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations
Anthony E. Lang et al.
MOVEMENT DISORDERS (2018)
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson's disease
Seung Pil Yun et al.
NATURE MEDICINE (2018)
Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease
Emily M. Rocha et al.
NEUROBIOLOGY OF DISEASE (2018)
Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model
Liping Zhang et al.
NEUROPEPTIDES (2018)
Exendin-4 attenuates neuronal death via GLP-1R/PI3K/Akt pathway in early brain injury after subarachnoid hemorrhage in rats
Zhiyi Xie et al.
NEUROPHARMACOLOGY (2018)
A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia
Martin Timo Henrich et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2018)
A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease
Ziyue Yuan et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2017)
Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Dilan Athauda et al.
LANCET (2017)
Animal models of α-synucleinopathy for Parkinson disease drug development
James B. Koprich et al.
NATURE REVIEWS NEUROSCIENCE (2017)
Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells
Theodora Panagaki et al.
SCIENTIFIC REPORTS (2017)
Insulin resistance and exendin-4 treatment for multiple system atrophy
Fares Bassil et al.
BRAIN (2017)
Exendin-4 Enhances Motor Function Recovery via Promotion of Autophagy and Inhibition of Neuronal Apoptosis After Spinal Cord Injury in Rats
Hao-Tian Li et al.
MOLECULAR NEUROBIOLOGY (2016)
Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease
Qing He et al.
MOLECULAR NEUROBIOLOGY (2016)
Fasudil, a Rho kinase inhibitor, promotes the autophagic degradation of A53T α-synuclein by activating the JNK 1/Bcl-2/beclin 1 pathway
Feng-Tao Liu et al.
BRAIN RESEARCH (2016)
A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF
Chenhui Ji et al.
BRAIN RESEARCH (2016)
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
Dilan Athauda et al.
DRUG DISCOVERY TODAY (2016)
The epidemiology of Parkinson's disease: risk factors and prevention
Alberto Ascherio et al.
LANCET NEUROLOGY (2016)
Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies
Maria Xilouri et al.
MOVEMENT DISORDERS (2016)
Insulin resistance and Parkinson's disease: A new target for disease modification?
D. Athauda et al.
PROGRESS IN NEUROBIOLOGY (2016)
Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2 antioxidant signaling pathways
Rania M. Abdelsalam et al.
JOURNAL OF NEUROCHEMISTRY (2015)
Insulin resistance in brain alters dopamine turnover and causes behavioral disorders
Andre Kleinridders et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Sensitive western blotting for detection of endogenous Ser129-phosphorylated α-synuclein in intracellular and extracellular spaces
Asuka Sasaki et al.
SCIENTIFIC REPORTS (2015)
Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson's Disease
Iciar Aviles-Olmos et al.
JOURNAL OF PARKINSONS DISEASE (2014)
The role of PI3K/AKT/mTOR pathway in the modulation of autophagy and the clearance of protein aggregates in neurodegeneration
David Heras-Sandoval et al.
CELLULAR SIGNALLING (2014)
Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice
Lital Rachmany et al.
AGE (2013)
Parkinson's disease, insulin resistance and novel agents of neuroprotection
Iciar Aviles-Olmos et al.
BRAIN (2013)
Exenatide and the treatment of patients with Parkinson's disease
Iciar Aviles-Olmos et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
100 years of Lewy pathology
Michel Goedert et al.
NATURE REVIEWS NEUROLOGY (2013)
Exendin-4 Ameliorates Motor Neuron Degeneration in Cellular and Animal Models of Amyotrophic Lateral Sclerosis
Yazhou Li et al.
PLOS ONE (2012)
Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease
Jinxia Zhou et al.
ACTA NEUROPATHOLOGICA (2011)
Autophagy: Renovation of Cells and Tissues
Noboru Mizushima et al.
CELL (2011)
被撤回的出版物: Effect of Ser-129 Phosphorylation on Interaction of α-Synuclein with Synaptic and Cellular Membranes (Retracted article. See vol. 295, pg. 13695, 2020)
Naomi P. Visanji et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Age and α-synuclein expression interact to reveal a dependence axons on endogenous Akt/PKB signaling
Sang Ryong Kim et al.
NEUROBIOLOGY OF DISEASE (2011)
Imaging biomarkers in Parkinson's disease
David J. Brooks et al.
PROGRESS IN NEUROBIOLOGY (2011)
Clinical Progression in Parkinson Disease and the Neurobiology of Axons
Hsiao-Chun Cheng et al.
ANNALS OF NEUROLOGY (2010)
Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model
Paola Luciani et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2010)
GLP-1 Receptor Stimulation Reduces Amyloid-beta Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease
Yazhou Li et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease
James B. Koprich et al.
MOLECULAR NEURODEGENERATION (2010)
Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease
Sehee Kim et al.
JOURNAL OF ENDOCRINOLOGY (2009)
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
Yazhou Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Autophagy in the pathogenesis of disease
Beth Levine et al.
CELL (2008)
Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease
Goran Bertilsson et al.
JOURNAL OF NEUROSCIENCE RESEARCH (2008)
Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model
Christelle Monville et al.
JOURNAL OF NEUROSCIENCE METHODS (2006)
Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology
RJ Griffin et al.
JOURNAL OF NEUROCHEMISTRY (2005)
分享论文
